Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
[Protocol 08-091]
Full Title :
PHASE I STUDY OF SINGLE AGENT PERIFOSINE FOR RECURRENT PEDIATRIC SOLID TUMORS
Purpose :
The purpose of this study is to find the highest dose of an investigational drug called perifosine that can be given safely in children with solid tumors that have returned or progressed despite prior therapy. Perifosine appears to block signals important in the development and growth of some cancers. It is taken orally (by mouth).
Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have a solid tumor that has returned or progressed despite treatment.
Patients must be age 18 or younger.
At least 3 weeks must have passed since completion of prior chemotherapy (6 weeks since nitrosoureas) and 4 weeks since radiation therapy and entry into the study.
For more information and to inquire about eligibility for this study, please contact Dr. Oren Becher at 212-639-2152 or Dr. Ira Dunkel at 212-639-2153.
